Business

Retinal Vein Occlusion (Formycon AG , Graybug Vision ,Kala Pharmaceuticals) – Pharmaceutical and Healthcare disease Pipeline Review, H2 2017

HTF Market Report released a new research document of 90 pages on industry titled as ‘Retinal Vein Occlusion – Pipeline Review, H2 2017’  with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as Formycon AG , Graybug Vision ,Kala Pharmaceuticals ,Lupin ,Mabion SA ,Novartis AG The report will help you gain market insights, future trends and growth prospects for forecast period of 2017-2022.

Request a sample report @ https://www.htfmarketreport.com/sample-report/829397-retinal-vein-occlusion-pipeline-review-1

Retinal Vein Occlusion – Pipeline Review, H2 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion – Pipeline Review, H2 2017, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.
Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 3, 9, 2 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=829397

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
– The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

Acucela Inc
Addmedica SAS
Aerpio Therapeutics Inc
Annexin Pharmaceuticals AB
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Clearside BioMedical Inc
Formycon AG
Graybug Vision Inc
Kala Pharmaceuticals Inc
Lupin Ltd
Mabion SA
Novartis AG
Ocular Therapeutix Inc
Ohr Pharmaceutical Inc
Regeneron Pharmaceuticals Inc
SciFluor Life Sciences LLC
ThromboGenics NV

Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/829397-retinal-vein-occlusion-pipeline-review-1

List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Retinal Vein Occlusion – Overview 8
Retinal Vein Occlusion – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Products under Development by Companies 12
Retinal Vein Occlusion – Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Retinal Vein Occlusion – Companies Involved in Therapeutics Development 22
Acucela Inc 22
Addmedica SAS 22
Aerpio Therapeutics Inc 22
Annexin Pharmaceuticals AB 23
Chengdu Kanghong Pharmaceuticals Group Co Ltd 23
Clearside BioMedical Inc 23
Formycon AG 24
Graybug Vision Inc 24
Kala Pharmaceuticals Inc 25
Lupin Ltd 25
Mabion SA 26
Novartis AG 26
Ocular Therapeutix Inc 27
Ohr Pharmaceutical Inc 27
Regeneron Pharmaceuticals Inc 28
SciFluor Life Sciences LLC 28
ThromboGenics NV 29
Retinal Vein Occlusion – Drug Profiles 30
ACU-6151 – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
aflibercept biosimilar – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
aflibercept biosimilar – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
aflibercept SR – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AKB-9778 – Drug Profile 34
Product Description 34
Mechanism Of

….Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/829397-retinal-vein-occlusion-pipeline-review-1

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218